Drugs / LEM-mR203
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06032000 Comparator | Nov 2023 → Mar 2025 | COVID-19 | Lemonex Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEM-mR203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06032000 ↗ |
| Modality | Messenger RNA (mRNA) | “The LEM-mR203 is a mRNA vaccine candidate” NCT06032000 ↗ |
| Route | Intramuscular | “healthy adults who will receive a single intramuscular injection of LEM-mR203” NCT06032000 ↗ |